Novel bridged bicyclic N-heterocycles

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof: in which X represents a group in which p represents an integer of 2 to 4; r represents an integer of 1 or 2; s represents 0 or 1; and A represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one or two heteroatoms selected from oxygen, nitrogen and sulphur, any amino nitrogen optionally substituted by a C 1-4 alkyl group, and when (p,r,s) is (2,2,0) or (2,2,1) any A comprising 2 heteroatoms is optionally C-substituted by a methyl group, and when (p,r,s) is (2,1,0), (2,1,1) or (3,1,0) any A comprising 2 heteroatoms is optionally C-substituted by C 1-2 alkyl and any A comprising one heteroatom is optionally C-substituted by a methyl group, and wherein compounds of formula (I) having two assymetric centres have the stereo-chemical configuration in which the group X and the (CH₂) r bridge are on the same side of the plane of the molecule which contains both bridgehead atoms and the ring carbon atom bonded to the group X.

Description: This invention relates to compounds having pharmaceutical activity, to a process for their preparation and their use as pharmaceuticals. 3-Methoxycarbonylquinuclidine is described in G. Lambrecht and E. Mutschler, Arzneim. forsh. 24 (11) 1725, 1974 to possess cholinergic activity. EP 0239309 (filed 18.03.87) discloses certain oxadiazoles useful in the treatment of senile dementia including 3-[3-(5-methyl-1,2,4-oxadiazol)-yl]quinuclidine hydrochloride, 3-[5-(3-methyl-1,2,4-oxadiazol)-yl]quinuclidine hydrochloride and 3-[2-(5-methyl-1,3,4-oxadiazol)-yl]quinuclidine hydrogen oxalate having a melting point of 97-105°C. A group of compounds has now been discovered which enhance acetylcholine function via an action at muscarinic receptors within the central nervous system and are therefore of potential use in the treatment and/or prophylaxis of dementia in mammals. Accordingly, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: in which X represents a group in which p represents an integer of 2 to 4; r represents an integer of 1 or 2; s represents 0 or 1; and A represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one or two heteroatoms selected from oxygen, nitrogen and excluding 3-[3-(5-methyl-1,2,4-oxadiazol)-yl]quinuclidine hydrochloride, 3-[5-(3-methyl-1,2,4-oxadiazol)-yl]quinuclidine hydrochloride, 3-[2-(5-methyl-1,3,4-oxadiazol)-yl]quinuclidine hydrogen oxalate having a melting point of 97-105°C. sulphur, any amino nitrogen optionally substituted by a C₁₋₄ alkyl group, and when (p,r,s) is (2,2,0) or (2,2,1) any A comprising 2 heteroatoms is optionally C-substituted by a methyl group, and when (p,r,s) is (2,1,0), (2,1,1) or (3,1,0) any A comprising 2 heteroatoms is optionally C-substituted by C₁₋₂ alkyl and any A comprising one heteroatom is optionally C-substituted by a methyl group, excluding 3-[3-(5-methyl- 1,2,4-oxadiazol)-yl]quinuclidine hydrochloride, 3-[5-(3-methyl-1,2,4-oxadiazol)-yl]quinuclidine hydrochloride, 3-[2-(5-methyl-1,3,4-oxadiazol)-yl]quinuclidine hydrogen oxalate having a melting point of 97-105°C. It will be understood that compounds of formula (I) having two assymetric centres have the stereo-chemical configuration in which the group X and the (CH₂) r bridge are on the same side of the plane of the molecule which contains both bridgehead atoms and the ring carbon atom bonded to the group X. This configuration will hereinafter be referred to as the exo configuration. Preferably, any ring carbon bonded to two heteroatoms in X is alkyl-substituted. Preferably any amino nitrogen is optionally substituted by C₁₋₂ alkyl. Preferably, any alkyl moiety in X is methyl. Examples of X include 3-methyl-1,2,4-oxadiazol-5-yl, 5-methyl-1,2,4-oxadiazol-3-yl, 5-methyl-1,3,4-oxadiazol-2-yl, 3-methyl-1,2,4-thiadiazol-5-yl, 1,3,4-oxadiazol-2-yl and 1,3-oxazol-2-yl. Preferred combinations of (p,r,s) include (2,2,0), (2,1,1), (3,1,1), (2,1,0) and (3,1,0). A subgroup of compounds within formula (I) is of formula (IA): wherein one of Y¹ and Z¹ represents nitrogen or CR₁, where R₁ is hydrogen or methyl, and the other represents CR₂ where R₂ is hydrogen or a methyl group, R₁ and R₂ not both being methyl. In compounds of formula (I) within formula (IA), suitable values for X include 3-methyl-1,2, 4-oxadiazol-5-yl, 5-(H or methyl)-1,3,4-oxadiazol-2-yl and 1,3-oxazol-2-yl. Examples of X are as described under formula (I). Another subgroup of compounds within formula (I) is of formula (IB): wherein Y² is nitrogen or CH, Z² is oxygen or NR₄ where R₄ is hydrogen or C₁₋₄ alkyl, and R₃ is hydrogen or methyl, R₃ and R₄ not both being an alkyl group. In compounds of formula (I) within formula (IB), suitable values for X include 5-methyl-1, 2,4-oxadiazol-3-yl. Examples of X are as described under formula (I). Suitable and preferred values for the remaining variables in formulae (IA) and (IB) are as described for the corresponding variables in formula (I). The compounds of formula (I) are capable of existing in enantiomeric forms. The invention extends to each of these stereoisomeric forms, and to mixtures thereof (including racemates). The different stereoisomeric forms may be separated one from the other by the usual methods, or any given isomer may be obtained by stereospecific or asymmetric synthesis. The compounds of formula (I) can form acid addition salts with acids, such as the conventional pharmaceutically acceptable acids, for example hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric, oxalic and methanesulphonic. The invention also provides a process for the preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, which process comprises: (a) cyclising a compound of formula (II): where R₁₀ is hydrogen or an N-protecting group, and either C is one, D is another and E is the remainder of -(CH₂) p -, -(CH₂) r - and -(CH₂) s -CHX'-CH₂- or groups convertible thereto, X' is X or a group convertible thereto and L¹ is a leaving group, or C is one and E is the other of -(CH₂) p - and -(CH₂) r - or groups convertible thereto and D represents -(CH₂) s -CHX''-CH₂-where X'' and L¹ together represent -COO-, and thereafter, optionally or as necessary and in any appropriate order, converting C, D and E to -(CH₂) p -, -(CH₂) r - and -(CH₂) s -CHX'-CH₂-, removing any R₁₀ protecting group, converting X' to X, interconverting X and/or forming a pharmaceutically acceptable salt, or (b) cyclising a compound of formula (III): where F is one and G is the other of -(CH₂) p - and -(CH₂) r - or groups convertible thereto, and one of Y³ and Y⁴ is -(CH₂) m -W and the other is -(CH₂) n V or -(CH₂) n L² where W and V are electron withdrawing groups, L² is a leaving group, m is 1 or 2 and n is O or 1, with the proviso that, when Y⁴ is -(CH₂) n V, n is 1, and Y⁴ is not -(CH₂) n L², and thereafter, optionally or as necessary and in any appropriate order, hydrolysing and decarboxylating the cyclisation product and converting the carbonyl group to CHX' where X' is X or a group convertible thereto, converting W to X' as defined, converting X' to X, converting F and G to -(CH₂) p - and -(CH₂) r - as appropriate, interconverting X and/or forming a pharmaceutically acceptable salt, with the proviso that m, n and q are such that the desired compound of formula (I) is obtained. Examples of leaving groups L¹ include halo such as chloro and hydroxy. Examples of L² include those given for L¹. Examples of electron withdrawing groups W include C₁₋₄ alkoxycarbonyl and cyano. The electron withdrawing group V is COL² or cyano, in which an example of L² is C₁₋₄ alkoxy such as ethoxy. In the group -(CH₂) s -CHX'-CH₂-, examples of X' include hydroxy and cyano. In the process variant (a), where L¹ is hydroxy and D is -CHOH-CH₂-, the cyclisation may be carried out by pyrolysis, by the method of D.O. Spry and H.S. Aaron, J. Org. Chem., 1969, 34 , 3674, to yield a compound where X' is hydroxy. Where E is -(CH₂) s COCH₂-, the cyclisation may be carried out under basic conditions where R₁₀ is benzyl (F.I. Carrol, A.M. Ferguson, and J.B. Lewis, J. Org. Chem. 31 , 2957, 1966). The resulting ketone may be reacted with tosylmethyl isocyanide to yield a compound where X' is cyano. Where L¹ and X'' together represent -COO-, the cyclisation is a rearrangement reaction which can be carried out under acid conditions in a polar solvent, such as hydrogen bromide in ethanol, at ambient temperature, to yield a compound where X' is a carboxy ester group. It is preferred to protect the nitrogen atom with an R₁₀ N-protecting group such as benzyl, which may be subsequently removed by hydrogenation over a suitable catalyst such as Pd/C. In the process variant (b), where Y³ and Y⁴ both contain carboxy ester groups the cyclisation is a Dieckmann reaction which is catalysed by a base such as potassium t-butoxide at elevated temperature in a solvent such as toluene. The resulting β-keto ester is hydrolysed and decarboxylated under conventional conditions such as heating at reflux in dilute hydrochloric acid. The carbonyl group may then be reduced to an X' hydroxy group with a suitable reducing agent such as sodium borohydride in ethanol at ambient temperature, or sodium in ethanol at elevated temperature, such as the boiling point of the solvent, under an inert atmosphere such as nitrogen, depending upon the stereochemistry required. Alternatively, the carbonyl group may be converted directly to an X' cyano group with a suitable reagent such as tosylmethylisocyanide in an inert solvent such as dry dimethoxyethane, at depressed temperature, under basic conditions such as the presence of potassium t-butoxide. Where Y³ is -(CH₂) n L², the cyclisation may be carried out as described in EP-0094742 under basic conditions such as sodium hydride and potassium t-butoxide, in an inert polar solvent such as dimethyl formamide. The conversions of the groups W and X', and interconversions of X, may be carried out conventionally with regard to the group X, see for example standard text books on heterocyclic chemistry such as 'Comprehensive Heterocyclic Chemistry', A.R. Katritzky and C.W. Rees, Pergamon, 1984. The X' or W group is first converted, as necessary, to a suitable starting group X' for the chosen conversion reaction to give the required group X. An X' hydroxy group may be converted to cyano by first converting it to a good leaving group such as mesyloxy or tosyloxy and then displacing it with cyanide ion. An X' carboxy group may be obtained by conventional de-esterification or an X' or W alkoxycarbonyl group. Where R₁₀ is an N-protecting group and X' or W is a benzyloxycarbonyl group, the de-esterification and deprotection steps may conveniently be effected simultaneously by conventional hydrogenation such as described above. Alternatively, an X' carboxy group may be obtained by conventional acid or base hydrolysis or an X' or W cyano group. An X' chlorocarbonyl group may be obtained by treatment of an X' carboxy group with thionyl chloride at elevated temperature. An X' aminocarbonyl group may be obtained by treatment of an X' chlorocarbonyl group with ammonia. Alternatively, an X' aminocarbonyl group may be obtained by partial alkaline hydrolysis of an X' or W cyano group, for example with an alkali metal hydroxide such as potassium hydroxide, in a polar solvent such as ethanol at elevated temperature. In some cases, it is preferable to carry out the partial hydrolysis using hydrogen peroxide and aqueous sodium hydroxide at room temperature. However, if this alternative procedure is adopted, the bridgehead nitrogen atom must be protected, preferably as a benzyl quaternary salt. When X represents 3-(C₁₋₂ alkyl)-1,2,4-oxadiazol-5-yl, reaction of an X' aminocarbonyl group with an acetal of an N,N-dimethyl (C₁₋₂)alkyl amide such as the dimethyl or diethyl acetal of N,N-dimethylacetamide, at elevated temperature yields the acyl amidine of formula (IVa): wherein R₅ is C₁₋₂ alkyl. The compound of formula (IVa) may then be cyclised with hydroxylamine, in the presence of acid, such as acetic acid, which may also function as the solvent. The reaction may be carried out at ambient temperature, the N-hydroxy acyl amidine intermediate isolated and then cyclised at elevated temperature, or alternatively in a one pot procedure without isolation of the intermediate. Alternatively an X' chlorocarbonyl group may be reacted with a C₂₋₃ alkanoic acid amide oxime, such as acetamide oxime, at elevated temperature in an inert, polar solvent such as chloroform, and the resulting substitution product cyclised in an inert solvent such as xylene, again at elevated temperature. When X represents 5-(C₁₋₂ alkyl)-1,2,4- oxadiazol-3-yl, the reaction of an X' cyano group may be carried out with hydroxylamine, in a polar solvent such as methanol to yield the corresponding amide oxime of formula (IVb): The compound of formula (IVb) may be cyclised using a suitable derivative of a C₂₋₃ alkanoic acid, for example a derivative of acetic acid such as the anhydride or a trialkylorthoacetate such as triethyl orthoacetate, the acid derivative acting as the solvent, at elevated temperature. When X represents 5-(H or C₁₋₂ alkyl)-1,3,4-oxadiazol-2-yl, an X' carboxy or carboxylic ester group may be converted to the acid hydrazide by conventional procedures. For example, an acid may be converted to a C₁₋₆ alkyl ester such as methyl, with the appropriate C₁₋₆ alkanol e.g. methanol under conventional esterification conditions, and the resulting ester reacted with hydrazine at elevated temperature to give the acid hydrazide of formula (IVc): The compound of formula (IVc) may then be cyclised by condensation with a suitable derivative of the appropriate C₁₋₃ alkanoic acid RCO₂H, for example a trialkyl ortho-ester, such as the triethyl ortho-ester, the acid derivative acting as the solvent, at elevated temperature. When X represents 1,3-oxazol-2-yl, an X' amino carbonyl group may be reacted with vinylene carbonate at elevated temperature in the presence of a strong acid such as polyphosphoric acid, which may also function as the solvent. When X represents 5-(H or methyl)-1,3-oxazol-2-yl, an X' carboxy group may first be converted to the carboxylic acid chloride and be reacted with a compound of formula NH₂CH₂CR(OR')₂, or the X' carboxy group may be reacted directly with the compound of formula NH₂CH₂CR(OR')₂ in the presence of a condensing agent such as dicyclohexylcarbodiimide or a chloroformate ester such as ethyl chloroformate, to give a compound of formula (IVd): which may be cyclised using a suitable dehydrating agent such as polyphosphoric acid, phosphorus oxychloride, phosphorus pentachloride, sulphuric acid or sulphonyl chloride, preferably polyphosphoric acid. 1,3-oxazol-2-yl groups 4-methyl-substituted may preferably be provided by cyclisation of an X' aminocarbonyl group with propargyl alcohol or the acetate ester thereof, in the presence of a dehydrating agent such as polyphosphoric acid using a catalyst such as HgSO₄, at elevated temperature. Alternative routes to optionally 4-methyl-substituted 1,3-oxazol-2-yl groups include: i) the condensation of an X' aminocarbonyl group with the appropriate compound BrCH₂COR at elevated temperature to give a compound of formula (I); or ii) the reaction of an X' carboxy group under basic conditions with the appropriate compound BrCH₂COR to give a compound of formula (IVe): which may be cyclised with ammonium chloride. During the reaction (i) above, the nitrogen atom of the bicyclic moiety may require protection. Compounds of formula (I) in which A contains a sulphur atom in place of oxygen may be prepared analogously. A sulphur-containing group X' is obtained by treatment of a carbonyl-containing group X' with either phosphorus pentasulphide or with Lawesson's reagent (S.Scheibye, B.S. Pederson and S.O. Lawesson, Bull. Soc. Chim. Belg., 1978, 87(3), 229). The resulting sulphur-containing group X' may then be converted to the required sulphur-containing group X analogously to the conversion of carbonyl-containing groups. In formulae (IVa) to (IVe), the variables are as defined in formula (I). In the above description, R represents H, methyl or ethyl as appropriate, and , R' represents C₁₋₆ alkyl such as methyl or ethyl. The invention also provides a process for the preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, which process comprises reacting a compound of formula (V): wherein p, r and s are as defined in formula (I), to convert the cyano group into a group X as defined in formula (I), and thereafter, optionally forming a pharmaceutically acceptable salt. Conversions of the cyano group are as described for conversions of X' cyano groups described above. Intermediates of formulae (II), (III) and (V) are known compounds (for example as described in EP-A-0094742) or may be prepared analogously. Intermediates of formula (II) where X'' and L¹ together represent -COO- are described in, for example, Kuthan et al ., Coll. Czechoslov. Chem. Comm., 1977, 42 , 283 or may be prepared therefrom by conventional hydrogenation of the pyridine ring over 5% Pt/C, and benzylation of the nitrogen atom by treatment with benzyl bromide and potassium carbonate in dry acetone. Intermediates of formula (II) where L¹ is a leaving group are described in, for example, Spry et at ., J. Org. Chem., 1969, 34 , 3674 and Hasse et al ., Chem. Ber., 1960, 93 , 1686. Intermediates of formula (III) are described in, for example, Martell et al ., J. Pharm. Sci., 1963, 52(4), 331, Sternbach et al., J.A.C.S., 1952, 74, 2215, Thill et al., J. Org. Chem., 1968, 33, 4376 and EP-0 094 742. Novel compounds of formula (IVa) to (IVe) also form part of the invention. Pharmaceutically acceptable salts of the compounds of formula (I) may be formed conventionally by reaction with the appropriate acid such as described above under formula (I). The compounds of the present invention enhance acetylcholine function via an action at muscarinic receptors within the central nervous system and are therefore of potential use in the treatment and/or prophylaxis of dementia. The present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The compositions may be in the form of tablets, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations such as oral or sterile parenteral solutions or suspensions. In order to obtain consistency of administration it is preferred that a composition of the invention is in the form of a unit dose. Unit dose presentation forms for oral administration may be tablets and capsules and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacantn, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulphate. The solid oral compositions may be prepared by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities or fillers. Such operations are of course conventional in the art. The tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating. Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents. For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, a preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound. The compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration. A method of treatment and/or prophylaxis of dementia in mammals including humans, comprises administering to the sufferer an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. The dose of the compound used in the treatment of such disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and the relative efficacy of the compound. However, as a general guide suitable unit doses may be 0.05 to 100 mg. for example 0.2 to 50mg; and such unit doses may be administered more than once a day, for example two or three times a day, so that the total daily dosage is in the range of about 0.01 to 10 mg/kg; and such therapy may extend for a number of weeks or months. Within the above indicated dosage ranges no toxicological effects are indicated for the compounds of the invention. In a further aspect the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance. The invention further provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prophylaxis of dementia. The invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment and/or prophylaxis of dementia. The following examples illustrate the invention and the following descriptions illustrate the preparation of intermediates thereto. Description 1 (±) 3-Cyano-1-azabicyclo[2.2.2]octane (D1) A mixture of 3-quinuclidinone (12.5g; 0.10 moles), tosylmethyl isocyanide (25.4g; 0.13 moles) and dry ethanol (10ml; 0.17 moles) in dry dimethoxyethane (350ml) was cooled in ice and treated portionwise with potassium t-butoxide (28.0g; 0.25 moles) while maintaining the temperature between 5°C and 10°C. After addition was complete the ice bath was removed and stirring was continued for a further 30 min. The reaction was then heated at 40°C for 2.5h. After cooling the precipitate was filtered off and the filtrate concentrated in vacuo . Purification on neutral alumina (Brockmann grade 1) using 2% methanol in ethyl acetate as eluant afforded the title compound as a syrup (10.0g: 74%) which crystallised on cooling. Description 2 (±) 1-Azabicyclo[2.2.2]octane-3-carboxamide (D2) A solution of (±) 3-cyano-1-azabicyclo[2.2.2]octane (D1) (4.1g; 0.03 moles) in ethanol (250ml) was treated with potassium hydroxide (7.9g; 0.12 moles) and the mixture was refluxed under nitrogen for 30h. After evaporation of solvent in vacuo , the residue was diluted with water (50ml), saturated with potassium carbonate and extracted into ethyl acetate (4 x 100ml). The combined organic extracts were washed with brine, dried (Na₂SO₄) and concentrated to give the title compound as a crystalline solid (3.3g; 72%). Oxalate salt m.p. 162-3°. Description 3 (±) 1-Azabicyclo[2.2.2]octane-3-N-[1-(dimethylamino)ethylidene]-carboxamide (D3) (±) 1-Azabicyclo[2.2.2]octane-3-carboxamide (D2) (0.85g; 5.5 mmoles) was treated with N,N-dimethylacetamide dimethyl acetal (5ml) at 120°C for 1.5h. Evaporation of excess reagent in vacuo afforded the title compound as an oil (1.3g) which was used in the next step without further purification. Ir (Film) 1560cm⁻¹, 1630cm⁻¹ Description 4 (±) 1-Azabicyclo[2.2.2]octane-3-(N-hydroxy)-carboximidamide (D4) A solution of hydroxylamine in methanol was prepared by addition of hydroxylamine hydrochloride (1.0g; 14.7 mmoles) to a solution of sodium methoxide generated from sodium (0.34g; 14.7 mmoles) in methanol (40ml). To this was added a solution of (±) 3-cyano-1-azabicyclo [2.2.2]octane (D1) (1.0g; 7.35 mmoles) in methanol (10ml). The mixture was refluxed for 18h. After evaporation of solvent in vacuo the residue was extracted with chloroform. Concentration of the organic solution in vacuo , followed by crystallisaion of the residue from methanol-ether afforded the title compound (0.57g: 46%) m.p. 188.5-190°C. Description 5 (±)exo-3-Cyano-1-azabicyclo[3.2.1]octane (D5) 1-Azabicyclo[3.2.1]octan-3-one (2.7g; 0.022 moles) in dry 1,2-dimethoxyethane (300ml), under nitrogen, was treated with tosylmethyl isocyanide (3.5g; 0.029 moles) and ethanol (4.6ml) at 0°C. Potassium t-butoxide (6.8g, 0.06 moles) was added portionwise at such a rate as to be able to maintain the temperature between 5°C and 10°C. The reaction mixture was allowed to warm to room temperature over 30min., and then heated at 40°C for a further 2.5h. The mixture was cooled and filtered and the residue washed with 1,2-dimethoxyethane. The combined filtrates were concentrated in vacuo and the residual gum purified by column chromatography on alumina eluting with 20% methanol in ethyl acetate. The title compound was obtained as an oil (2.0g; 66%). Ir ν (CN) 2225 cm⁻¹. Description 6 (±) exo-1-Azabicyclo[3.2.1]octane-3-carboxamide (D6) A solution of (±) exo-3-cyano-1-azabicyclo[3.2.1]octane (D5) (1.0g; 0.0074 moles) in ethanol (200ml) was treated with potassium hydroxide (2.5g; 0.029 moles) and the mixture was refluxed under nitrogen for 30h. After evaporation of solvent in vacuo , the residue was diluted with water (50ml), saturated with potassium carbonate and extracted into ethyl acetate (4 x 100ml). The combined organic extracts were washed with brine, dried (Na₂SO₄) and concentrated to give the title compound as an orange solid (0.36g; 32%). Description 7 (±) exo-1-Azabicyclo[3.2.1]octane-3-N-[1-(dimethylamino)-ethylidene]-carboxamide (D7) (±) exo-1-Azabicyclo[3.2.1]octane-3-carboxamide (D6) (0.36g) was treated with N,N-dimethylacetamide dimethyl acetal (4ml) at 120°C for 1.5h. Evaporation of excess reagent in vacuo afforded the title compound as an oil which was used in the next step without further purification. Description 8 (±) 1-Azabicyclo[2.2.2]octane-3-carboxylic acid hydrazide (D8) (±) Methyl 1-azabicyclo[2.2.2]octane-3-carboxylate (0.36g; 2.1 mmoles) and hydrazine hydrate (0.35ml; 7.0 mmoles) were heated at 120°C for 2h. The reaction was diluted with water (10ml), saturated with potassium carbonate and extracted into chloroform (3 x 15ml). Combined organic extracts were dried (Na₂S0₄) and concentrated to give the title compound as a pale oil (0.36g; 100%) which was used in the next stage without further purification. Description 9 (±) exo-6-Cyano-1-azabicyclo[3.2.1]octane (D9) A solution of ± 1-azabicyclo[3.2.1]octane-6-one (10g; 0.08mole) which had been dried in vacuo, in dry 1,2 dimethoxyethane (400ml) under an atmosphere of nitrogen was treated with p-tosylmethyl isocyanide (23.4g; 0.12mole) and absolute ethanol (6g; 0.13mole) at 0°C with stirring. Potassium t-butoxide (22.6g; 0.2mole) was then added at such a rate that the temperature remained below 5°C. when the addition was complete, the solution was allowed to warm to room temperature whilst stirring was continued and, after a further 30 min, the reaction was warmed to 40°C for 30 min. The reaction mixture was then cooled to 10°C and filtered. The filtrate was concentrated in vacuo to a gum which was extracted with several portions of ether. The ether extract was separated and concentrated in vacuo to a yellow oil. This was chromatographed on alumina in a gradient of 3-15% methanol in ethyl acetate. The first fraction, eluted with 10% methanol in ethyl acetate, was distilled on a Kugelrohr at approximately 120°C and 0.1mm Hg to afford (±) ex o-6-cyano-1-azabicyclo[3.2.1]octane (D9) (4.3g; 40%) as a colourless oil, ¹H Nmr (CDCl₃), δ: 1 38-1.80 (4H, m, 3-C H ₂, 4-C H ₂); 2.62 (1H, m, s-C H ); 2.80-3.0 (5H, m, 2-C H ₂, 8-C H ₂, 6-C H ); 3.16 (1H, d,d, J=14Hz, 5Hz, 7-C H ); 3.36 (1H, d,d,d, J=14Hz, 8Hz, 2Hz, 7-CH). ¹³C Nmr (CDCl₃), δ: 19.0, 29.8, 32.4, 41.5, 54.4, 57.5, 60.0, 122.7, i.r. νmax 2225cm⁻¹. The second fraction eluted with 12% methanol in ethyl acetate was distilled on a Kugelrohr at 130°C and 0.1mm Hg to afford a semi-solid gum (4.1g, 38%) which was recrystallised from pentane to afford (±) endo-6-cyano-1-azabicyclo[3.2.1]octane (1.6g), m.p. 92-95°C, ¹H Nmr (CDCl₃), δ: (1.42-1.52 (1H, m) and 1.76-2.0 (3H, m) (together 3-CH₂, 4-CH₂), 2.48 (1H, m, 5-CH), 2.64-2.70 (1H, m) and 2.82-3.02 (4H, m) (together 2-CH₂, 8-CH₂, 6-CH), 3.13 (1H, d,d,d J=2Hz, 4Hz, 13Hz, 7-CH); 3.37 (1H, d,d, J=11Hz, 13Hz 7-CH), ¹³C nmr (CDCl₃) δ: 18.6, 27.56, 32.1, 37.9, 55.0, 55.7, 60.8, 120.48, i.r. νmax 2225cm⁻¹. Description 10 (±) exo-1-Benzyl-6-cyano-1-azoniabicyclo[3.2.1]octane bromide (D10) A solution of (±) exo -6-cyano-1-azabicyclo[3.2.1]octane (D9) (2g; 0.015mole) in ether (50ml) was treated with benzyl bromide (2.5g; 0.015mole) at room temperature overnight. The solution was filtered to afford (±) exo -1-benzyl-6-cyano-1-azoniabicyclo[3.2.1]octane bromide (D10) (4.5g, 99%) m.p. 250-253°C, ¹H Nmr (CD₃OD), δ: 1.7-2.0 (4H, m, 3-C H ₂ and 4-C H ₂), 3.1 (1H, m, 5-C H ), 3.3-3.7 (4H, m, 2-CH₂, 8-CH₂), 3.8-4 (2H, m, 6-CH, 7-CH), 4.1-4.2 (1H, m, 7-CH), 4.725 (1H, d, J=14Hz) and 4.775 (1H, d, J=14Hz) (together CH₂Ph), 7.6 (5H, m, Ph). Description 11 (±) exo-1-Azabicyclo[3.2.1]octane-6-carboxamide (D11) A solution of (±) exo -1-benzyl-6-cyano-1-azoniabicyclo[3.2.1]octane bromide (D10) (4.5g; 0.015mole) in methanol (250ml) was treated with hydrogen peroxide (10ml, 100vol) and aqueous sodium hydroxide (5ml, 10%) at room temperature. After 1h the reaction was adjusted to pH 4 with acetic acid and concentrated in vacuo to a gum. The residue was taken up in methanol (250ml) and 10% palladium on charcoal (0.5g) added and stirred under an atmosphere of hydrogen until the uptake of hydrogen ceased. The reaction was then filtered through celite and concentrated in vacuo to a gum. The residue was taken up in saturated aqueous potassium carbonate and extracted exhaustively with chloroform. The chloroform extracts were dried over anhydrous sodium sulphate and concentrated in vacuo to afford (±) exo -1-azabicyclo[3.2.1]octane-6-carboxamide (D11) (1.3g; 58%) which was recrystallised from ether, m.p. 145-150°C, ¹H nmr (CDCl₃), δ 1.3-1.8 (4H, m, 3-C H ₂, 4-C H ₂); 2.4 (1H, m, 5-C H ); 2.6-3.0 (5H, m, 2-C H ₂, 8-C H ₂, 6-C H ); 3.15 (2H, d, J=4Hz, 7-C H ₂); 6.0 (2H, m, N H ₂). Description 12 (±) exo-3-Cyano-1-azabicyclo[3.3.1]nonane (D12) A solution of 1-azabicyclo[3.3.1]nonan-3-one (4.7g, 0.034 mole) and tosylmethylisocyanide (7.2g, 0.037 mole) in dry dimethoxyethane (150ml) at 0°C was treated with ethanol (3ml) followed by the portionwise addition of potassium tert-butoxide (8.3g, 0.075 mole) over 0.5h. The mixture was stirred at 0°C for a further 1h and then at room temperature for 20h. The mixture was treated with water (25ml), then saturated by adding solid potassium carbonate and extracted with ethyl acetate. The organic extract was dried (K₂CO₃), filtered and concentrated in vacuo to leave a dark red oil. This was chromatographed on silica gel eluting initially with chloroform, increasing to 8% methanol/chloroform to give the title compound (D12) as a red oil (2.64g, 52%). Nmr (CDCl₃) δ: 1.30-2.40 (7H, m, 3 x CH₂, CH) 2.80-3.50 (7H, m, 3 x CH₂N, CHCN) IR ν (CN) 2225 cm⁻¹ Description 13 (±) exo-1-Azabicyclo[3.3.1]nonane-3-carboxamide (D13) A solution of (±) exo-3-cyano-1-azabicyclo[3.3.1]nonane (D12) (1.20g, 0.008 mole) in concentrated hydrochloric acid (10ml) was heated at 100°C for 3h. The mixture was evaporated to dryness under reduced pressure, and dried in vacuo overnight. The residue was dissolved in thionyl chloride (12ml), one drop of DMF added, and the mixture heated under reflux with stirring for 5h. Excess thionyl chloride was evaporated under reduced pressure and toluene (2 x 20ml) used to azeotrope out the final traces. The resulting acid chloride was dissolved in dichloromethane (20ml) at 0°C, and a solution of ammonia gas in dichloromethane (50ml) was added with stirring. The organic suspension was then washed with saturated potassium carbonate solution (10ml), and the aqueous layer then extracted with chloroform (2 x 50ml). The organic extracts were combined, dried (Na₂SO₄), filtered and evaporated to dryness under reduced pressure. Column chromatography on basic alumina eluting with chloroform/methanol (0-10%) afforded (±) exo-1-azabicyclo[3.3.1]nonane-3-carboxamide (D13) (0.77g, 55%), which was used without further purification. Description 14 (±) cis-4-Benzyl-2-oxo-2a,3,4,5,6,6a-hexahydro-7H-furo[3,4-c]pyridine (D14) A solution of 2-oxo-7H-furo[3,4-c]pyridine hydrochloride salt (9.43g, 0.055mole) in a mixture of ethanol (150ml), water (30ml) and 5M hydrochloric acid (5ml) was hydrogenated over 5% Pt/C (400mg) at 45°C and 150 psi for 15h. The catalyst was filtered off through a pad of kieselguhr and the filtrate concentrated in vacuo . The residue was basified with saturated potassium carbonate solution and extracted with chloroform (3 x 70ml). The organic extract was dried (Na₂SO₄) and concentrated in vacuo to leave a brown oil (8.5g), which was dissolved in dry acetone (200ml) and treated with anhydrous potassium carbonate (16.5g) and benzyl bromide (7.2ml). The mixture was stirred at room temperature for 2h, then diluted with water (400ml) and extracted with ethyl acetate (3 x 150ml). The combined extracts were dried (Na₂SO₄) and concentrated in vacuo to give a brown oil, which was chromatographed on silica gel eluting with ether to give the title compound (D14) as a pale yellow oil (3.15g, 25%). ¹H Nmr (CDCl₃) δ: 1.52-1.65 (1H, m, 5ax) 1.77-1.86 (1H, m, 5eq) 1.95 (1H, dt, 6ax, J=2.5Hz and J=13.5Hz) 2.31 (1H, dd, 2ax, J=5Hz and J=13.5Hz) 2.42-2.52 (1H, m, 4ax) 2.59-2.65 (1H, m, 3eq) 2.66-2.73 (1H, m, 6eq) 3.21-3.28 (1H, m, 2eq) 3.45-3.62 (2H, m, C H ₂Ph) 3.96-4.02 (1H, m, 1 x CH₂OCO) 4.18-4.25 (1H, m, 1 x CH₂OCO) 7.20-7.34 (5H, m, P h CH₂) Description 15 (±) exo-Ethyl 1-benzyl-1-azoniabicyclo[2.2.1]heptane-3-carboxylate bromide (D15) (±) cis -4-Benzyl-2-oxo-2a,3,4,5,6,6a-hexahydro-7H-furo[3,4-c]pyridine (D14, 2.80g, 0.012 mole) was treated with a saturated solution of hydrogen bromide in ethanol (150ml) and the mixture stirred at room temperature for 9 days. The mixture was concentrated in vacuo and the residue basified with saturated potassium carbonate solution then extracted with chloroform (3 x 80ml). The combined extracts were dried and concentrated in vacuo to give the title compound (D15) as a yellow gum (4.0g, 98%), which was used without purification. Description 16 (±) exo-Methyl 1-azabicyclo[2.2.1]heptane-3-carboxylate (D16) A solution of (±) exo -ethyl 1-benzyl-1-azoniabicyclo[2.2.1]-heptane-3-carboxylate bromide (D15, 4.0g, 0.012mole) in ethanol (150ml) plus glacial acetic acid (2ml) was hydrogenated over 10% Pd/C (500mg) at atmospheric pressure and 40°C until uptake of hydrogen ceased. The catalyst was filtered off through a pad of kieselguhr and the filtrate concentrated in vacuo to leave a beige semi-solid, which was treated with 8M hydrochloric acid (70ml) aid heated under reflux for 2h. The solution was concentrated in vacuo to give a beige solid, which was treated with methanolic hydrogen chloride (100ml) and heated under reflux for 30 minutes followed by 2 days at room temperature. The solution was concentrated in vacuo and the residue basified with saturated sodium hydrogen carbonate solution, then extracted with chloroform (3 x 60ml). The combined extracts were dried (Na₂SO₄) and concentrated to give an orange oil, which was distilled in a Kugelröhr apparatus (b.p. approx. 110-120°C at 0.4mm) to give the title compound (D16) (1.3g, 70%) as a colourless oil. A portion was converted to its oxalate salt and recrystallised from methanol/ether, m.p. 134-136°C. Oxalate:- ¹H Nmr (d⁶DMSO) δ: 1.65-1.76 (1H, m) 1.90-2.05 (1H, m) 2.85-2.95 (1H, m) 2.95-3.15 (4H, m) 3.22-3.32 (1H, m) 3.35-3.50 (2H, m) 3.68 (3H, s, COOCH₃) Analysis: C₈H₁₃NO₂. C₂H₂O₄ requires: C: 48.98; H: 6.12; N: 5.71% found: C: 48.97; H: 6.17; N: 5.51% M.S.: Calculated mass for C₈H₁₃NO₂ = 155.0946 Observed mass = 155.0946 Description 17 Acetamide Oxime (D17) A solution of sodium methoxide (prepared from 2.90g, 0.126 mole of sodium) in methanol (50ml) was added dropwise ever 10 mins to a stirred solution of hydroxylamine hydrochloride (8.7g, 0.126 mole) in methanol (100ml). The mixture was stirred at room temperature for 1h, then the precipitate was filtered off and the filtrate treated with acetonitrile (6.8ml, 0.13 mole) and then heated under reflux. After 6h, a further 6.8ml of acetonitrile was added and reflux continued for a further 16h. The solution was then concentrated in vacuo to give the title compound (D17) as a white solid (7.7g, 83%), m.p. 123-127°C. Example 1 (±) 3-(3-Methyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo [2.2.2]octane (E1) (±) 1-Azabicyclo[2.2.2]octane-3-N-[1-dimethylamino]-ethylidene]-carboxamide (D3) (1.28g; 6.0 mmoles) was treated with a solution of hydroxylamine hydrochloride (0.53g; 7.5 mmoles) in aqueous sodium hydroxide (7.5ml of 1M NaOH) and then diluted with dioxane (7.5ml) followed by glacial acetic acid (10ml). After stirring at room temperature for 30 min., the mixture was heated at 90°C for 1h. The reaction was concentrated in vacuo , diluted with, water (20ml) and saturated with potassium carbonate. After extraction into chloroform (4 x 20ml)the organic layers were dried (Na₂SO₄) and concentrated in vacuo to give a crude oil. Removal of polar impurities by extraction of the product into ether and filtration afforded the title compound as an oil (0.85g; 72%) which was converted into the oxalate salt, m.p. 112-115°C (acetone/methanol/ether). Oxalate: Ir (KBr) νC=N 1580cm⁻¹ ¹H Nmr (d₆-DMSO) δ: 1.55-1.85 (2H,m), 1.85-2.10 (2H,m), 2.37 (3H,s), 2.43 (1H,m), 3.15-3.30 (4H,m) 3.50-3.83 (3H,m) ¹³C Nmr (CD₃OD + d₆-DMSO) δ: 12.08, 20.04, 23.90, 25.63, 33.52, 46.90, 47.22, 49.92, 166.40, 168.34, 180.10 Analysis: C₁₀H₁₅N₃O. C₂H₂O₄ requires: C: 50.88; H: 6.05; N: 14.83 found: C: 50.69; H: 6.37; N: 14.73 Example 2 (±) 3-(5-Methyl-1,2,4-oxadiazol-3-yl)-1-azabicyclo [2.2.2]octane (E2) (±) 1-Azabicyclo[2.2.2]octane-3-(N-hydroxy)-carboximidamide (D4) (0.37g; 2.2 mmoles) was heated with acetic anhydride (5ml) at 120°C for 2h. Excess reagent was evaporated in vacuo . The residue was treated with water (15ml) and then saturated with potassium carbonate. After extraction into ethyl acetate (4x20ml) the combined organic layers were dried (Na₂SO₄) and concentrated in vacuo . Removal of polar impurities by extraction of product into ether afforded the title compound as a colourless gum which was purified as the oxalate salt. Oxalate: Ir (KBr) νC=N 1580cm⁻¹ ¹H Nmr (d₆-DMSO) δ: 1.66-1.82 (2H,m), 1.85-2.15 (2H,m), 2.34 (1H,m), 2.60 (3H,s), 3.16-3.38 (4H,m), 3.40-3.70 (3H,m). ¹³C Nmr (d₆-DMSO) δ: 11.99, 18.51, 22.82, 23.98, 31.30, 45.13, 45.44, 47.90, 164.70, 170.12, 177.50. Example 3 (±) exo-3-(3-Methyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo [3.2.1]octane (E3) (±) 1-Azabicyclo[3.2.1]octane-3-N-[1-(dimethylamino)ethylidene]-carboxamide prepared as outlined in Description 7 was treated with a solution of hydroxylamine hydrochloride (0.22g; 3.1 mmoles) in aqueous sodium hydroxide (3.1ml of 1M NaOH) and then diluted with dioxane (5ml) followed by glacial acetic acid (10ml). After stirring at room temperature for 30 min., the mixture was heated at 90°C for 1h. The reaction was concentrated in vacuo , diluted with water (20ml) and saturated with potassium carbonate. After extraction into chloroform (4 x 50ml) the organic layers were dried (Na₂SO₄) and concentrated in vacuo to give a crude oil. Removal of polar impurities by extraction of the product into ether and filtration afforded the title compound as an oil which was converted into the oxalate salt. m.p. 149-152° (acetone) Oxalate: Ir ν (C=N) 1570 cm⁻¹ MS calculated mass for C₁₀H₁₅N₃0 = 193.1206 observed mass = 193.1216 ¹H Nmr (d₆-DMSO) δ: 1.84-2.04 (2H,m), 2.06-2.2 (2H,m), 2.44 (3H,s), 2.71 (1H,m), 3.1-3.15 (1H,m), 3.4-3.5 (4H,m), 3.6-3.65 (1H,m), 3.86 (1H,heptet). ¹³C Nmr (d₆-DMSO) δ: 11.02, 26.69, 27.17, 32.18, 32.63, 48.88, 52.71, 57.26, 164.54, 166.68, 178.26. Example 4 (±) 3-(5-Methyl-1,3,4-oxadiazol-2-yl)-1-azabicyclo [2.2.2]octane (E4) (±) 1-Azabicyclo[2.2.2]octane-3-carboxylic acid hydrazide (D8) (0.36g; 2.1 mmoles) and triethyl orthoacetate (3ml) were heated at 120°C for 2h. Excess triethyl orthoacetate was evaporated in vacuo and the residue was heated for a further 2h at 140°C. The reaction was diluted with water (10ml), saturated with potassium carbonate and extracted into ether (3 x 15ml). Combined organic extracts were dried (Na₂S0₄) and concentrated to give the title compound as an oil (0.29g; 72%), which was purified as the oxalate salt. m.p. 147-8° (Acetone-methanol). Oxalate: Ir (KBr) ν C=N 1590, 1560 cm⁻¹ ¹H Nmr (d₆-DMSO) δ: 1.60-1.80 (2H,m), 1.80-2.08 (2H,m), 2.38 (1H,m), 2.48 (3H,s), 3.15-3.32 (4H,m), 3.52-3.73 (3H,m) ¹³C Nmr (d₆-DMSO) δ: 10.5, 18.6, 22.5, 23.6, 30.8, 45.1, 45.3, 47.6, 164.3, 164.5, 166.0 Example 5 ( ±) 3-(1,3-Oxazol-2-yl)-1-azabicyclo[2.2.2]octane (E5) A stirred mixture of (±) 1-azabicyclo[2.2.2]octane-3-carboxamide (D2) (2.3g; 0.015 moles) and vinylene carbonate (1.33g; 0.016 moles) in polyphosphoric acid (50g) was placed in an oil bath at 120° and the temperature was raised to 180° over a period of 45 min. After cooling the reaction was treated with ice and washed with ether (100ml). The pH of the aqueous solution was adjusted to 9 with 40% sodium hydroxide and potassium carbonate was then added until saturation point. Extraction with ether (4 x 100ml) followed by drying (Na₂SO₄) and concentration in vacuo afforded a crude oil (1.45g). Purification on neutral alumina (Brockmann grade 1) using a graded eluant of 2%-6% methanol in ethyl acetate produced the title compound as a pale yellow oil (0.74g; 28%) which was converted into the oxalate salt, m.p. 98-101°C (acetone-methanol). Oxalate: Ir (KBr) ν (C=N) 1560cm⁻¹ ¹H Nmr (d₆-DMSO) δ: 1.55 (1H,m), 1.73 (1H,m), 1.88-2.10 (2H,m), 2.37 (1H,m), 3.12-3.35 (4H,m), 3.55-3.72 (3H,m), 7.24 (1H,s), 8.14 (1H,s). ¹³C Nmr (d₆-DMSO) δ: 18.73, 22.48, 24.24, 32.89, 45.06, 45.38, 48.12, 126.79, 140.47, 163.50, 164.82 Analysis: C₁₀H₁₄N₂O. C₂H₂O₄ requires : C: 53.73; H: 6.01; N: 10.44 found: C: 53.52; H: 6.11; N: 10.30 Example 6 (±) exo-6-(3-Methyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo [3.2.1]octane (E6) A solution of (±) exo -1-azabicyclo[3.2.1]octane-6-carboxamide (D11) (0.4g; 0.0026mole) in N,N-dimethylacetamide dimethyl acetal (2.5g) was heated at 120°C for 1.5h. The excess reagent was then evaporated in vacuo and the crude ethylidine carboxamide treated with a solution of hydroxylamine hydrochloride (0.226g; 0.0033mole) in aqueous sodium hydroxide (3.2ml, 1M). Acetic acid (5ml) and dioxan (5ml) were added immediately to the stirred reaction mixture and, after 30 minutes at room temperature, the temperature was raised to 90°C for 1h. The reaction was then concentrated in vacuo and the residue taken up in aqueous saturated potassium carbonate. The aqueous solution was extracted with chloroform (4 x 20ml) and the organic extract was dried over sodium sulphate and concentrated in vacuo to a gum. Chromatography on alumina in a gradient of 3-10% methanol in ethyl acetate afforded 2 fractions. The major second fraction afforded (±) exo -6-(3-methyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo[3.2.1]octane (220mg, 44%) as a colourless oil. The oxalate salt was prepared by treating the oil (200mg) in ether with oxalic acid (100mg) in methanol (1ml). The oxalate salt (270mg) was recrystallised from methanol/ether, m.p. 137-138°C, found: C, 50.63; H, 6.15; N, 15.05%. C₁₂H₁₇N₃O₅ requires: C, 50.88; H, 6.05; N, 14.83%, ¹H nmr (d₆-DMSO), δ: 1.7-2.1 (4H, m, 3-C H ₂, 4-C H ₂); 2.325 (3H, s, C H ₃); 2.82 (1H, m, 5-C H ); 3.2-3.35 (4H, m, 2-C H ₂; 8-C H ₂); 3.6-3.7 (1H, m, 6- H ); 3.8-3.95 (2 H , m, 7-C H ₂); 4.6 (2H, br, O H ). Example 7 (±) 3-(3-Methyl-1,2,4-thiadiazol-5-yl)-1-azabicyclo [2.2.2]octane (E7) Compound E7 is prepared analogously to compound E1 from the nitrile D1. The nitrile is first converted via the carboxamide to the thioamide by treatment with either phosphorus pentasulphide or with Lawesson's reagent (S.Scheibye, B.S. Pederson and S.O. Lawesson, Bull. Soc. Chim. Belg., 1978, 87(3), 229. The thioamide is treated with N,N-dimethylacetamide dimethylacetal at ambient temperature, to yield the thioacyl amidine D18: which is cyclised by treatment with a suitable hydroxylamine derivative such as hydroxylamine-O-sulphonic acid in the presence of pyridine, in an alcohol such as methanol or ethanol at ambient temperature, or O-(mesitylene sulphonyl)hydroxylamine in dichloromethane at a temperature of 0-25°C. Example 8 (±) 3-(1,3,4-Oxadiazol-2-yl)-1-azabicyclo[2.2.2]octane (E8) A mixture of (±) 1-azabicyclo[2.2.2]octane-3-carboxylic acid hydrazide (D8, 0.5g, 3.0 mmoles) and triethyl orthoformate (5ml) was heated under nitrogen at 120° for 8h. Excess triethyl orthoformate was evaporated in vacuo and the residue was heated at 140° under nitrogen for 2.5h. The reaction was diluted with water (10ml) and saturated with potassium carbonate. Extraction into ether (4 x 10ml) followed by drying (Na₂SO₄) and concentration in vacuo afforded the title compound (E8) as a yellow oil (0.13g; 25%) which was purified as the oxalate salt (mp = 146-148°C from acetone-methanol). Oxalate: Ir (KBr) ν C=N 1565cm⁻¹ ¹H Nmr (d₆-DMSO) δ: 1.50-1.85 (2H, m) 1.85-2.10 (2H, m) 2.40 (1H, m) 3.12-3.35 (4H, m) 3.55-3.85 (3H, m) 9.28 (1H, s) ¹³C Nmr (d₆-DMSO) δ: 18.72, 22.53, 23.75, 30.92, 45.10, 45.42, 47.79, 155.10, 164.76, 166.03 Example 9 (±) exo-3-(1,3-Oxazol-2-yl)-1-azabicyclo[3.3.1]nonane (E9) A stirred mixture of (±) exo-1-azabicyclo[3.3.1]nonane-3-carboxamide (D13) (0.77g, 0.0046 mole) and vinylene carbonate (0.398g, 0.0047 mole) in polyphosporic acid (PPA) (17g) was heated in an oil bath at 120°C and the temperature raised to 140°C over 1.5h. After cooling, the mixture was treated with ice (50ml), allowed to stand for 1h, and washed with diethyl ether (50ml). The aqueous solution was adjusted to pH9 with 40% aqueous sodium hydroxide solution, and solid potassium carbonate added until saturation point. The solution was extracted with diethyl ether (4 x 200ml) , dried (Na₂SO₄), filtered and evaporated to dryness under reduced pressure to give an orange oil (360mg). Column chromatography on neutral alumina eluting with methanol (1%)/ethyl acetate gave (±) exo-3-(1,3-oxazol-2-yl)-1-azabicyclo[3.3.1]nonane (E9) (160mg, 18%) which was converted into the oxalate salt, m.p. 137-138°C. Free base: Ir (CHCl₃) ν (C=N) 1565cm⁻¹ Oxalate: ¹H Nmr (d₆-DMSO, 400MHz) δ: 1.68-2.07 (5H, m, 2 x CH₂, CH) 2.15-2.30 (3H, m, CH₂, CH) 3.30-3.54 (4H, m, 2 x CH₂N) 3.70-4.02 (2H, m, CH₂N) 7.18 (1H, s, oxazole H CN) 8.10 ((1H, s, oxazole H CO) ¹³C Nmr (d₆-DMSO, 100MHz) δ: 18.95, 24.08, 25.62, 30.00, 31.46, 50.05, 51.23, 51.50, 126.67, 139.65, 163.62 and 164.41. Analysis: C₁₁H₁₆N₂O.C₂H₂O₄ requires C: 55.31; H: 6.43; N: 9.92; found C: 55.16; H: 6.27; N: 9.66 M.S. Calculated mass for C₁₁H₁₆N₂O = 192.1263 observed mass = 192.1250 Example 10 (±) exo-3-(3-Methyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo [2.2.1]heptane (E10) A solution of (±) exo -methyl 1-azabicyclo[2.2.1]heptane-3-carboxylate (D16) (950mg, 0.0062 mole) in 8M hydrochloric acid (70ml) was heated under reflux for 2.5h, then concentrated in vacuo to give a yellow semi-solid. This material was treated with thionyl chloride (20ml) and heated under reflux for 4.5h. The solution was concentrated in vacuo and the residue dissolved in absolute chloroform (130ml), treated with acetamide oxime (D17, 550mg, 0.0074 mole) and heated under reflux for 4h. The reaction mixture was basified with saturated potassium carbonate solution and extracted with chloroform (3 x 70ml). The combined extracts were dried (Na₂SO₄) and concentrated to leave an orange oil, which was treated with xylene (100ml) and heated under reflux for 1.5h, using a Dean and Stark head to trap water formed. The reaction mixture was concentrated in vacuo to leave an orange oil, which was chromatographed on silica gel eluting with 2% methanol/chloroform to give the title compound (E10) as a colourless oil. This was converted to its oxalate salt and recrystallised from ethanol/ether to give a white solid (190mg, 11%) m.p. 116-120°C. Oxalate:- ¹H Nmr (d⁶-DMSO) δ: 1.75-1.87 (1H, m) 1.95-2.10 (1H, m) 2.35 (3H, s, CH₃) 3.10-3.40 (5H, m), 3.53-3.70 (3H, m) M.S. Calculated mass for C₉H₁₃N₃O = 179.1059 Observed mass = 179.1041 Biological Activity Radio ligand Binding Cerebral cortex from Hooded Lister rats (Olac, UK) is homogenised in 2.5 vols ice-cold 50mM tris buffer pH 7.7 (at 25°C). After centrifugation at 25,000 x g at 4°C for 15 min the pellet is resuspended in 2.5 vols buffer and the wash repeated 3 times more. The final resuspension is in 2.5 volumes and the homogenates are stored in 1ml aliquots at -20°C. Incubations (total volume 2ml) are prepared using the above buffer with the addition of 2mM magnesium chloride in the 3H-Oxotremorine-M (3H-OXO-M) experiments. For 3H-Quinuclidinyl Benzilate (3H-QNB), 1ml of stored membranes is diluted to 30ml and 0.1ml mixed with test compound and 0.27nM (c. 25,000 cpm) 3H-QNB (Amersham International). For 3H-OXO-M, 1ml of membranes is diluted to 6ml and 0.1ml mixed with test compound and 2nM (c. 250,000 cpm) 3H-OXO-M (New England Nuclear). Non-specific binding of 3H-QNB is defined using 1µM Atropine sulphate (2µM Atropine) and of 3H-OXO-M using 10µM Oxotremorine. Non-specific binding values typically are 5% and 25% of total binding, respectively. Incubations are carried out at 37°C for 30 min and the samples filtered using whatman GF/B filters. (In the 3H-OXO-M experiments the filters are presoaked for 30 min in 0.05% polyethylenimine in water). Filters are washed with 3 x 4ml ice-cold buffer. Radioactivity is assessed using a Packard BPLD scintillation counter, 3ml Pico-Fluor 30 (Packard) as scintillant. This test provides an indication of the muscarinic binding activity of the test compound. The results are obtained as IC₅₀ values (i.e. the concentration which inhibits binding of the ligand by 50%) for the displacement of the muscarinic agonist 3H-OXO-M and the muscarinic antagonist 3H-QNB. The ratio IC₅₀(3H-QNB)/IC₅₀(3H-OXO-M) gives an indication of the agonist character of the compound. Agonists typically exhibit a large ratio; antagonists typically exhibit a ratio near to unity. The results are shown in Table 1:

Claims: Claims for the following Contracting States : BE, CH, DE, FR, GB, GR, IT, LI, LU, NL, SE A compound of formula (I) or a pharmaceutically acceptable salt thereof: in which X represents a group in which p represents an integer of 2 to 4; r represents an integer of 1 or 2; s represents 0 or 1; and A represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one or two heteroatoms selected from oxygen, nitrogen and sulphur, any amino nitrogen optionally substituted by a C₁₋₄ alkyl group, and when (p,r,s) is (2,2,0) or (2,2,1) any A comprising 2 heteroatoms is optionally C-substituted by a methyl group, and when (p,r,s) is (2,1,0), (2,1,1) or (3,1,0) any A comprising 2 heteroatoms is optionally C-substituted by C₁₋₂ alkyl and any A comprising one heteroatom is optionally C-substituted by a methyl group, and wherein compounds of formula (I) having two assymetric centres have the stereo-chemical configuration in which the group X and the (CH₂) r bridge are on the same side of the plane of the molecule which contains both bridgehead atoms and the ring carbon atom bonded to the group X, excluding 3-[3-(5-methyl-1,2,4-oxadiazol)-yl]quinuclidine hydrochloride, 3-[5-(3-methyl-1,2,4-oxadiazol)-yl]quinuclidine hydrochloride, 3-[2-(5-methyl-1,3,4-oxadiazol)-yl]quinuclidine hydrogen oxalate having a melting point of 97-105°C. A compound according to claim 1, wherein any ring carbon bonded to two heteroatoms in X is alkyl-substituted as defined in claim 1. A compound according to claim 1, wherein any amino nitrogen is optionally substituted by C₁₋₂ alkyl. A compound according to any preceding claim, wherein any alkyl moiety in X is methyl. A compound according to claim 1 of formula (IA): wherein one of Y¹ and Z¹ represents nitrogen or CR₁, where R₁ is hydrogen or methyl, and the other represents CR₂ where R₂ is hydrogen or a methyl group, R₁ and R₂ not both being methyl. A compound according to claim 5, wherein X is 3-methyl-1,2,4-oxadiazol-5-yl, 5-methyl-1,3,4-oxadiazol-2-yl, 3-methyl-1,2,4-thiadiazol-5-yl or 1,3-oxazol-2-yl. A compound according to claim 1 of formula (IB): wherein Y² is nitrogen or CH, Z² is oxygen or NR₄ where R₄ is hydrogen or C₁₋₄ alkyl, and R₃ is hydrogen or methyl, R₃ and R₄ not both being an alkyl group. A compound according to claim 7, wherein X is 5-methyl-1,2,4-oxadiazol-3-yl. A compound according to any preceding claim, wherein (p,r,s) is (2,2,0), (2,1,1), (3,1,1), (2,1,0) or (3,1,0). (±) 3-(3-Methyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo[2.2.2]octane, oxalate salt, (±) 3-(5-methyl-1,2,4-oxadiazol-3-yl)-1-azabicyclo [2.2.2]octane, oxalate salt, (±) exo-3-(3-methyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo[3.2.1]octane, (±) 3-(5-methyl-1,3,4-oxadiazol-2-yl)-1-azabicyclo[2.2.2]octane, oxalate salt having a melting point of 147-8°C, (±) 3-(1,3-oxazol-2-yl)-1-azabicyclo[2.2.2]octane, (±) exo-6-(3-methyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo[3.2.1]octane, (±) 3-(3-methyl-1,2,4-thiadiazol-5-yl)-1-azabicyclo[2.2.2]octane, (±) 3-(1,3,4-oxadiazol-2-yl)1-azabicyclo [2.2.2]octane, (±) exo-3-(1,3-oxazol-2-yl)-1-azabicyclo [3.3.1]nonane or (±) exo-3-(3-methyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo[2.2.1]heptane, or pharmaceutically acceptable salt thereof. A process for the preparation of a compound according to claim 1, which process comprises: (a) cyclising a compound of formula (II): where R₁₀ is hydrogen or an N-protecting group, and either C is one, D is another and E is the remainder of -(CH₂) p -, -(CH₂) r - and -(CH₂) s -CHX'-CH₂- or groups convertible thereto, X' is X or a group convertible thereto and L¹ is a leaving group, or C is one and E is the other of -(CH₂) p - and -(CH₂) r - or groups convertible thereto and D represents -(CH₂) s -CHX''-CH₂-where X'' and L¹ together represent -COO-, and thereafter, optionally or as necessary and in any appropriate order, converting C, D and E to -(CH₂) p -, -(CH₂) r - and -(CH₂) s -CHX'-CH₂-, removing any R₁₀ protecting group, converting X' to X, interconverting X and/or forming a pharmaceutically acceptable salt, or (b) cyclising a compound of formula (III): where F is one and G is the other of -(CH₂) p - and -(CH₂) r - or groups convertible thereto, and one of Y³ and Y⁴ is -(CH₂) m -W and the other is -(CH₂) n V or -(CH₂) n L² where W and V are electron withdrawing groups, L² is a leaving group, m is 1 or 2 and n is 0 or 1, with the provisos that, when Y⁴ is -(CH₂) n V, n is 1, and Y⁴ is not -(CH₂) n L², and thereafter, optionally or as necessary and in any appropriate order, hydrolysing and decarboxylating the cyclisation product and converting the carbonyl group to CHX' where X' is X or a group convertible thereto, converting W to X' as defined, converting X' to X, converting F and G to -(CH₂) p - and -(CH₂) r - as appropriate, interconverting X and/or forming a pharmaceutically acceptable salt, with the proviso that m, n and q are such that the desired compound of formula (I) is obtained. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier. A compound according to claim 1 for use as an active therapeutic substance. A compound according to claim 1 for use in the treatment and/or prophylaxis of dementia in mammals. The use of a compound according to claim 1 for the preparation of a medicament for the treatment and/or prophylaxis of dementia in mammals. A process for the preparation of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, which process comprising reacting a compound of formula (V): wherein p, r and s are as defined in claim 1, to convert the cyano group into a group X as defined in formula (I), and thereafter, optionally forming a pharmaceutically acceptable salt. Claims for the following Contracting State : ES A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof: in which X represents a group in which p represents an integer of 2 to 4; r represents an integer of 1 or 2; s represents 0 or 1; and A represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one or two heteroatoms selected from oxygen, nitrogen and sulphur, any amino nitrogen optionally substituted by a C₁₋₄ alkyl group, and when (p,r,s) is (2,2,0) or (2,2,1) any A comprising 2 heteroatoms is optionally C-substituted by a methyl group, and when (p,r,s) is (2,1,0), (2,1,1) or (3,1,0) any A comprising 2 heteroatoms is optionally C-substituted by C₁₋₂ alkyl and any A comprising one heteroatom is optionally C-substituted by a methyl group, and wherein compounds of formula (I) having two assymetric centres have the stereo-chemical configuration in which the group X and the (CH₂) r bridge are on the same side of the plane of the molecule which contains both bridgehead atoms and the ring carbon atom bonded to the group X, excluding 3-[3-(5-methyl-1,2,4-oxadiazol)-yl]quinuclidine hydrochloride, 3-[5-(3-methyl-1,2,4-oxadiazol)-yl]quinuclidine hydrochloride, 3-[2-(5-methyl-1,3,4-oxadiazol)-yl]quinuclidine hydrogen oxalate having a melting point of 97-105°C, which process comprises (a) cyclising a compound of formula (II): where R₁₀ is hydrogen or an N-protecting group, and either C is one, D is another and E is the remainder of -(CH₂) p -, -(CH₂) r - and -(CH₂) s -CHX'-CH₂- or groups convertible thereto, X' is X or a group convertible thereto and L¹ is a leaving group, or C is one and E is the other of -(CH₂) p - and (CH₂) r - or groups convertible thereto and D represents -(CH₂) s -CHX''-CH₂-where X'' and L¹ together represent -COO-, and thereafter, optionally or as necessary and in any appropriate order, converting C, D and E to -(CH₂) p -, -(CH₂) r - and -(CH₂) s -CHX'-CH₂- removing any R₁₀ protecting group, converting X' to X, interconverting X and/or forming a pharmaceutically acceptable salt, or (b) cyclising a compound of formula (III): where F is one and G is the other of -(CH₂) p - and -(CH₂) r - or groups convertible thereto, and one of Y³ and Y⁴ is -(CH₂) m -W and the other is -(CH₂) n V or -(CH₂) n L² where W and V are electron withdrawing groups, L² is a leaving group, m is 1 or 2 and n is 0 or 1, with the provisos that, when Y⁴ is -(CH₂) n V, n is 1, and Y⁴ is not -(CH₂) n L², and thereafter, optionally or as necessary and in any appropriate order, hydrolysing and decarboxylating the cyclisation product and converting the carbonyl group to CHX' where X' is X or a group convertible thereto, converting W to X' as defined, converting X' to X, converting F and G to -(CH₂) p - and -(CH₂ r - as appropriate, interconverting X and/or forming a pharmaceutically acceptable salt, with the proviso that m, n and q are such that the desired compound of formula (I) is obtained. A process for the preparation of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, which process comprising reacting a compound of formula (V): wherein p, r and s are as defined in claim 1, to convert the cyano group into a group X as defined in formula (I), and thereafter, optionally forming a pharmaceutically acceptable salt. A process according to claim 1 or 2, wherein any ring carbon bonded to two heteroatoms in X is alkyl-substituted as defined in claim 1. A process according to claim 1 or 2, wherein any amino nitrogen is optionally substituted by C₁₋₂ alkyl. A process according to any preceding claim, wherein any alkyl moiety in X is methyl. A process according to claim 1 or 2 for preparing a compound of formula (IA): wherein one of Y¹ and Z¹ represents nitrogen or CR₁, where R₁ is hydrogen or methyl, and the other represents CR₂ where R₂ is hydrogen or a methyl group, R₁ and R₂ not both being methyl. A process according to claim 6, wherein X is 3-methyl-1,2,4-oxadiazol-5-yl, 5-methyl-1,3,4-oxadiazol-2-yl, 3-methyl-1,2,4-thiadiazol-5-yl or 1,3-oxazol-2-yl. A process according to claim 1 or 2 for preparing a compound of formula (IB): wherein Y² is nitrogen or CH, Z² is oxygen or NR₄ where R₄ is hydrogen or C₁₋₄ alkyl, and R₃ is hydrogen or methyl, R₃ and R₄ not both being an alkyl group. A process according to claim 8, wherein X is 5-methyl-1,2,4-oxadiazol-3-yl. A process according to any preceding claim, wherein (p,r,s) is (2,2,0), (2,1,1), (3,1,1), (2,1,0) or (3,1,0). A process according to claim 1 or 2 for preparing (±) 3-(3-methyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo[2.2.2]octane, oxalate salt, (±) 3-(5-methyl-1,2,4-oxadiazol-3-yl)-1-azabicyclo[2.2.2]octane, oxalate salt, (±) exo-3-(3-methyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo[3.2.1]octane, (±) 3-(5-methyl-1,3,4-oxadiazol-2-yl)-1-azabicyclo[2.2.2]octane, oxalate salt having a melting point of 147-8°C, (±) 3-(1,3-oxazol-2-yl)-1-azabicyclo[2.2.2]octane, (±) exo-6-(3-methyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo[3.2.1]octane, (±) 3-(3-methyl-1,2,4-thiadiazol-5-yl)-1-azabicyclo[2.2.2]octane, (±) 3-(1,3,4-oxadiazol-2-yl)-1-azabicyclo [2.2.2]octane, (±) exo-3-(1,3-oxazol-2-yl)-1-azabicyclo[3.3.1]nonane, or (±) exo-3-(3-methyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo[2.2.1]heptane, or a pharmaceutically acceptable salt thereof. The use of a compound as defined in claim 1 or 2 for the preparation of a medicament for the treatment and/or prophylaxis of dementia in mammals.

Inventors: HADLEY MICHAEL STEWART, ORLEK BARRY SIDNEY, ROSENBERG HOWARD ELLIOTT, WADSWORTH HARRY JOHN, HADLEY, MICHAEL STEWART, ORLEK, BARRY SIDNEY, ROSENBERG, HOWARD ELLIOTT, WADSWORTH, HARRY JOHN
Applicants: BEECHAM GROUP PLC
Application year: 1987
Main classification: C07D453
IPC codes: C07D453, A61P25, C07D471, C07D487, C07D451, A61K31